What is Heart Test Laboratories Inc. Common Stock?
, a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.
HSCS · Verdict
Moderate reward · high risk
HSCS has limited near-term tailwinds — volatility and cash flow weigh on the model output.
Based on 88% data coverage
HSCS · Verdict
Weak vs peers
-171108% free-cash-flow margin
-201500% net margin · -220% ROE
Current ratio 0.59
Model-based scoring. For information only — not financial advice.
, a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 8.87M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.